Table 1.
Characteristics of patients included in the four datasets for meta-analysis
| Not taking anticoagulant therapy (n=5076) | Taking anticoagulant therapy (n=351) | From cohorts with some patients taking anticoagulant therapy (n=3550) | CT angiography (n=868) | ||
|---|---|---|---|---|---|
| Sex | |||||
| Female | 1971/4884 (40%) | 135 (38%) | 1449 (41%) | 379 (44%) | |
| Male | 2913/4884 (60%) | 216 (62%) | 2101 (59%) | 489 (56%) | |
| Age, years | 67 (56–76) | 76 (69–82) | 69 (58–78) | 70 (57–79) | |
| Previous stroke | 607/4560 (13%) | 77/317 (24%) | 481/3308 (15%) | 97/829 (12%) | |
| Previous intracerebral haemorrhage* | 179/2753 (7%) | 9/246 (4%) | 113/2051 (6%) | 29/805 (4%) | |
| Previous ischaemic stroke* | 246/2755 (9%) | 53/246 (22%) | 213/2051 (10%) | 70/805 (9%) | |
| History of hypertension | 3787/5050 (75%) | 291 (83%) | 2739/3547 (77%) | 616/866 (71%) | |
| History of diabetes mellitus | 727/4197 (17%) | 82/343 (24%) | 626/3475 (18%) | 137/807 (17%) | |
| History of liver disease | 256/3360 (8%) | 14/220 (6%) | 96/1946 (5%) | 15/360 (4%) | |
| History of excessive alcohol consumption† | 568/3091 (18%) | 20/177 (11%) | 221/1455 (15%) | 73/554 (13%) | |
| Antiplatelet therapy at symptom onset | 913/5030 (18%) | 102 (29%) | 855/3543 (24%) | 225/837 (27%) | |
| Anticoagulant therapy at symptom onset | 0 | 351 (100%) | 349/3547 (10%) | 87/841 (10%) | |
| Systolic blood pressure at presentation, mm Hg | 177 (158–198); n=4882 | 170 (147–190); n=320 | 177 (157–197); n=3333 | 175 (150–200); n=860 | |
| Blood glucose at presentation, mmol/L | 7·0 (5·9–8·7); n=4265 | 7·4 (6·0–9·3); n=340 | 7·0 (5·9–8·7); n=3417 | 7·3 (6·1–8·9); n=864 | |
| Platelet count (×109/L) at presentation | 221 (181–266); n=3857 | 209 (174–260); n=289 | 222 (185–267); n=2284 | 227 (181–273); n=862 | |
| Glasgow Coma Scale score at presentation | |||||
| 3–6 | 285/4564 (6%) | 42/342 (12%) | 248/3502 (7%) | 73/831 (9%) | |
| 7–12 | 1033/4564 (23%) | 81/342 (24%) | 824/3502 (24%) | 193/831 (23%) | |
| 13–14 | 1157/4564 (25%) | 70/342 (20%) | 830/3502 (24%) | 151/831 (18%) | |
| 15 | 2089/4564 (46%) | 149/342 (44%) | 1600/3502 (46%) | 414/831 (50%) | |
| NIHSS score at presentation | 12 (7–18); n=2661 | 13 (7–17); n=126 | 12 (7–17); n=2014 | 14 (6–18); n=325 | |
| Time from symptom onset to baseline imaging, h | 2·4 (1·3–4·7) | 3·3 (1·7–6·4) | 2·2 (1·3–4·2) | 2·9 (1·5–5·1) | |
| Intracerebral haemorrhage volume on baseline imaging, mL | 13·2 (6·3–30·0) | 16·0 (6·4–39·0) | 13·4 (6·6–30·3) | 15·0 (6·6–34·1) | |
| Lobar location of intracerebral haemorrhage on baseline imaging | 1080/4920 (22%) | 129/344 (38%) | 907/3439 (26%) | 267/866 (31%) | |
| Intraventricular haemorrhage present on baseline imaging | 1834/4980 (37%) | 157/348 (45%) | 1265/3452 (37%) | 344 (40%) | |
| CT angiogram spot sign present | .. | .. | .. | 204 (24%) | |
| >6 mL intracerebral haemorrhage growth | 1009 (20%) | 110 (31%) | 771 (22%) | 177 (20%) | |
| >6 mL or >33% intracerebral haemorrhage growth | 1301 (26%) | 139 (40%) | 986 (28%) | 219 (25%) | |
Data are n (%), n/N (%), or median (IQR). NIHSS=National Institutes of Health Stroke Scale.
*
Available in a subgroup of cohorts that quantified the subtype of previous stroke. Not all cohorts that quantified the subtype included both intracerebral haemorrhage and ischaemic stroke.
†
Definition of excessive consumption varied across cohorts.